CYP2C19 and coronary artery disorder: Because studies have found that even after the application of CYP2C19 gene testing guidance and the administration of standard DAPT drug dose treatment, 20–30% of patients with coronary heart disease still have high platelet reactivity (HPR), and about 5–6% of patients after stent implantation have DAPT resistance, which is more likely to occur in patients in East Asia (23, 24).